Whether NHI should reimburse the daily use of pemigatinib 13.5 mg in advanced ICC patients with FGFR2 fusions/rearrangements or keep the current reimbursement option only for the mFOLFOX or 5-FU regimen, based on the trial evidence. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.